tumor cell biology program - Sylvester Comprehensive Cancer Center

More documents

Recommendations

Info

UM/Sylvester Comprehensive Cancer Center Scientific Report 2002
INTRODUCTION W. Jarrard Goodwin, M.D., F.A.C.S. Director Bi-directional translational research, with ideas flowing from the laboratory bench to the patient’s bedside and back again, is the essence of a comprehensive cancer center. The University of Miami Sylvester Comprehensive Cancer Center supports a large group of basic laboratory scientists and a growing cadre of physician scientists who work together to help establish better treatment regimens for cancer patients everywhere. The State of Florida, the citizens of South Florida, and the University of Miami are investing in this important work. This report demonstrates the wisdom of that investment. I am proud of our scientists, and of their research product, as reported on the pages that follow. The content of this report follows our operational structure. Our scientists are grouped into multidisciplinary research programs, which address important aspects of the cancer problem. The scientific programs that we have established (Tumor Cell Biology, Tumor Immunology, Viral Oncology, Cancer Prevention and Control, and Clinical Oncology Research) reflect our strengths and our priorities. This selection of programs is what makes us unique among the many fine cancer centers in our great country. We are focusing our attention on facilitating translational research in each of these programs. The clinical testing of targeted therapies, using molecules identified as promising by our scientists, is among our most exciting and significant activities. Our scientists work within the established research programs, and with physicians in UM/ Sylvester’s 13 multidisciplinary, site-based oncology groups, to design and conduct the clinical trials necessary to test the value of these new treatments. Current examples include: • A Phase III trial of antiviral drugs along with interferon for patients with HIV-related lymphomas • A Phase I trial of arsenic plus ascorbic acid in patients with refractory multiple myeloma • A Phase I trial of a vaccine in refractory, non-small cell lung cancer • A Phase II trial of vitamin D, along with radiation therapy, in hormone refractory prostate cancer Conducting clinical trials, with patients as research subjects, is a weighty responsibility. The Clinical Research Services resource is especially important to UM/Sylvester in that it is charged with assisting the principal investigator with the safe and effective conduct of each trial. I am grateful to the research nurses and data managers who work on the front lines of this effort. All who do this work recognize that our patients are the real heroes. The addition of Dr. Joseph D. Rosenblatt to UM/ Sylvester’s leadership team in 2001 was especially significant. Dr. Rosenblatt serves as division chief of Hematology-Oncology in the Department of Medicine and scientific director of UM/Sylvester. As a world-class physician scientist and an experienced leader, he is the ideal individual to provide direction for the translational research program outlined above. His recruitment confirms our commitment to this effort. Dr. Rosenblatt has quickly proved himself to be a terrific colleague, and it is truly a personal pleasure for me to formally recognize his many contributions to UM/Sylvester here. I would like to dedicate this report to two inspiring individuals and a remarkable volunteer group. We lost Dr. Kasi Sridhar to lymphoma this past year. He combined all the best qualities seen in each of us, and served as the president of our medical staff for six years. We miss him dearly. Mr. Stuart Danoff was a UM/Sylvester founder, a member of our Board of Governors, and chaired our Research Committee. His courage remains a constant inspiration to me. And in an era when most volunteer groups struggle to maintain their momentum, the Papanicolaou Corps for Cancer Research celebrated their 50 th anniversary this year, with a gift of nearly $2 million. The Corps has grown to 37 units and 12,000 members, and has donated more than $7 million to support cancer research during the past six years. Their tireless efforts continue to impress and amaze me. We are slowly winning the war against cancer. Age-adjusted death rates for most cancer sites and for cancer overall began to decline in the early 1990s, and that decline has accelerated. Nearly as important, the quality of life experienced by those waging a personal battle with cancer also has improved. But that is not good enough. We must do more, and the pages of this report demonstrate our passion to make a difference. I hope that you find this report to be useful, and I welcome your comments. UM/Sylvester Comprehensive Cancer Center Scientific Report 2002 i
Page 1: TABLE OF CONTENTS SCIENTIFIC REPORT
Page 5 and 6: The Tumor Cell Biology Program cont
Page 7 and 8: ership of Dr. Goodwin, and with the
Page 9 and 10: SYLVESTER COMPREHENSIVE CANCER CENT
Page 11 and 12: TUMOR CELL BIOLOGY PROGRAM PROGRAM
Page 13 and 14: Dimitropoulou, A and Bixby, JL. Reg
Page 15 and 16: ticle from ascites tumor cell micro
Page 17 and 18: PUBLICATIONS Carraway, KL III, Ross
Page 19 and 20: treated with rho 123, lactic acid a
Page 21 and 22: ments which then interact with a HA
Page 23 and 24: PUBLICATIONS Mayeda, A, Screaton, G
Page 25 and 26: PUBLICATIONS Rudd, KE. Novel interg
Page 27 and 28: PUBLICATIONS Ing, D, Zang, J, Dzau,
Page 29 and 30: PUBLICATIONS Welsh, CF, Assoian, RK
Page 31 and 32: TUMOR IMMUNOLOGY PROGRAM PROGRAM LE
Page 33 and 34: PUBLICATIONS Adkins, B. Apoptosis o
Page 35 and 36: cDNA microarray in order to perform
Page 37 and 38: they are “doubly cytotoxic defici
Page 39 and 40: PUBLICATIONS Charyulu, VI and Lopez
Page 41 and 42: suppression of c-Myc. In addition C
Page 43 and 44: HIGHLIGHTS/DISCOVERIES • The mole
Page 45 and 46: Giovana R. Thomas, M.D. Assistant P
Page 47 and 48: VIRAL ONCOLOGY PROGRAM PROGRAM LEAD
Page 49 and 50: sensitive cell lines as well as inh
Page 51 and 52: Lawrence H. Boise, Ph.D. Assistant
Page 53 and 54:
ated apoptosis in adult T-cell leuk
Page 55 and 56:
CANCER PREVENTION AND CONTROL PROGR
Page 57 and 58:
Michael H. Antoni, Ph.D. Professor
Page 59 and 60:
women assigned to CBSM showed incre
Page 61 and 62:
women, greater involvement in relig
Page 63 and 64:
Adarsh M. Kumar, Ph.D. Research Ass
Page 65 and 66:
CLINICAL ONCOLOGY RESEARCH PROGRAM
Page 67 and 68:
PUBLICATIONS Lokeshwar, BL, Schwart
Page 69 and 70:
Phase III Randomized Study of Whole
Page 71 and 72:
gical resections and reconstruction
Page 73 and 74:
PUBLICATIONS Johnson, BW and Boise,
Page 75 and 76:
fects of stressors and stress manag
Page 77 and 78:
N. Concerns about breast cancer and
Page 79 and 80:
DESCRIPTION OF RESEARCH Lung Cancer
Page 81 and 82:
Clinical Oncology Research Program
Page 83 and 84:
SHARED RESOURCES DESCRIPTION Shared
Page 85 and 86:
a result, outstanding images can be
Page 87 and 88:
DIVISION OF BIOSTATISTICS DIVISION
Page 89 and 90:
DIVISION OF INFORMATICS DIVISION CH
Page 91 and 92:
SCIENTIFIC REPORT PUBLICATIONS 1999
Page 93 and 94:
Heylbroek, C, DeLuca, C, Lin, R, Ba
Page 95 and 96:
ing protein, ICP8. Journal of Biolo
Page 97 and 98:
Price-Schiavi, SA, Perez, A, Barco,
Page 99 and 100:
Fischl, MA. Antiretroviral therapy
Page 101 and 102:
cavity reconstruction. Archives of
Page 103 and 104:
Frankfurt, OS and Krishan, A. Ident
Page 105 and 106:
Lokeshwar, VB, Young, MJ, Goudarzi,
Page 107 and 108:
Schoell, WM, Mirhashemi, R, Liu, B,
Page 109 and 110:
Nakagawa, N, Parel, JM and Murray,
Page 111 and 112:
ond Edition, Granoff, A; Webster, R
Page 113 and 114:
lon mimicking a primary invasive bl
Page 115 and 116:
ducible factor-1, activator protein
show all

tumor cell biology program - Sylvester Comprehensive Cancer Center

Create successful ePaper yourself

Delete template?

Save as template?